Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference, taking place June 15-16, 2026. The fireside chat will be available on demand beginning June 15 at 7:00 a.m. EDT, according to a press release.
The presentation underscores Helus Pharma's focus on addressing large unmet needs in mental health. The company's proprietary NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, with the goal of providing durable improvements for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma is currently advancing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, the company is developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
The company, operating in Canada, the United States, the United Kingdom, and Ireland, aims to improve the treatment landscape with its class-leading data. For more information, visit the company's newsroom at https://ibn.fm/HELP.
The H.C. Wainwright conference provides a platform for Helus Pharma to discuss its progress with investors and industry experts. The fireside chat is expected to cover the company's clinical development milestones, regulatory achievements, and future outlook.
Helus Pharma, formerly known as Cybin Inc. and founded in 2019, is committed to helping minds heal through the development of NSAs. The company's stock is traded on NASDAQ and Cboe Canada under the ticker HELP.
This announcement comes as the mental health treatment landscape continues to evolve, with a growing emphasis on novel mechanisms of action like serotonergic agonism. Helus Pharma's focus on neuroplasticity-based approaches may offer new hope for patients with treatment-resistant conditions.
The full press release is available at https://ibn.fm/KsnJW.
